<DOC>
	<DOCNO>NCT00008190</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Interleukin-2 may stimulate person 's white blood cell kill leukemia cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation interleukin-2 treating patient acute leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Interleukin-2 Treating Patients With Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy busulfan , cyclophosphamide , etoposide follow autologous peripheral blood stem cell transplantation interleukin-2 patient high-risk acute leukemia . - Determine efficacy immunomodulatory therapy term relapse-free survival patient treat regimen . - Determine hematopoietic reconstitution , relapse , survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : Following course mobilization chemotherapy , patient receive prim therapy comprise filgrastim ( G-CSF ) interleukin-2 completion leukapheresis . Patients receive oral busulfan 4 time daily day -8 -5 , cyclophosphamide IV continuously day -4 -3 , etoposide IV 2 hour day -4 . For patient unable receive cyclophosphamide etoposide , melphalan IV administer instead day -3 -2 . Autologous peripheral blood stem cell ( PBSC ) reinfused day 0 . Patients receive G-CSF daily begin day 0 continue blood count recover follow interleukin-2 subcutaneously daily begin completion G-CSF therapy continue 6 month . Patients follow weekly 1 month monthly thereafter . PROJECTED ACCRUAL : A total 19-25 patient accrue study within 3-5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm acute leukemia Highrisk due following : Cytogenetic abnormality involve 5q , 7q , 8q , 11q23 , ( 9 ; 22 ) WBC great 100,000/mm3 Prior myelodysplastic syndrome Complete remission ( CR ) last less 12 month No favorable cytogenetic parameter ( e.g. , ( 15 ; 17 ) , inv16 , ( 8 ; 21 ) ) CR follow standard antileukemic therapy confirm bone marrow evaluation Second third CR allow Ineligible high priority national institutional study allogeneic peripheral blood stem cell transplantation PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 1.5 time normal SGOT SGPT less 1.5 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : LVEF least 45 % receive cyclophosphamide Normal electrocardiogram OR Approval cardiologist Pulmonary : DLCO le 60 % predict OR Approval pulmonologist Other : Not pregnant nursing No concurrent illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>